[1] Grodski S, Delbridge L. An update on papillary microearcinoma. Curr Opin Oncol, 2009, 21(1):1-4.
[2] Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med, 1994, 97(5):418-428.
[3] Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999):temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg, 2002, 26(8):879-885.
[4] Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170:A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.J Clin Endocrinol Metab, 2004, 89(8):3668-3676.
[5] Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 2006, 16(2):109-142.
[6] Ma C, Kuang A, Xie J. Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. Cochrane Database Syst Rev, 2009, (1):CD006988.
[7] Pluijmen MJ, Eustatia-Rutten C, Goslings BM, et al. Effects of lowiodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf), 2003,58(4):428-435.
[8] Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med, 1998, 25(3):242-246.
[9] Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning:an ongoing dilemma. Thyroid, 1997, 7(2):277-280.
[10] Edmonds C J, Hayes S, Kermode JC, et al. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol, 1977, 50(599):799-807.
[11] Torres MS, Ramirez L, Simkin PH, et al. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in nurmal subjects.J Clin Endocrinol Metab, 2001, 86(4):1660-1664.
[12] Robbins RJ, Schlumberger MJ. The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med, 2005, 46(Suppl 1):28S-37S.
[13] de Klerk JM, de Keizer B, Zelissen PM. Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy. Nucl Med Commun, 2000, 21(6):529-532.
[14] Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric:radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med, 2006, 47(10):1587-1591.
[15] Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am, 2007, 36(3):807-822.
[16] Maxon HR 3rd, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach:outcome and validation in 85 patients. J Nucl Med, 1992, 33(6):1132-1136.
[17] Souza Rosário PW, Barroso AL, Rezende LL, et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases:an unnecessary cost or a relevant contribution?. Clin Nucl Med, 2004, 29(12):795-798.
[18] Fatourechi V, Hay ID, Mullan BP. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with difterentiated thyroid cancer?. Thyroid, 2000, 10(7):573-577.
[19] Sherman SI, Tielens ET, Sostre S. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab, 1994, 78(3):629-634.
[20] McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outeomes in thyroid cancer. Ann Med, 2002, 34(7-8):554-564.
[21] Kloos RT, Mazzaferri EL. A single recombinant human thyrotropinstimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab, 2005, 90(9):5047-5057.
[22] Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab, 2008, 93(1):76-81.
[23] Eustatia-Rutten CF, Smit JW, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf), 2004, 61(1):61-74.
[24] Chung JK, Park YJ, Kim TY, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf), 2002, 57(2):215-221.